Legacy Financial Group (Iowa)
TXMD icon

Legacy Financial Group (Iowa)’s TherapeuticsMD TXMD Stock Holding History

Legacy Financial Group (Iowa)’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$302 – 475
2023
Q3 		$302 Buy
+100
New +$378 ﹤0.01% 547

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legacy Financial Group (Iowa)'s TXMD Position: Q4 2023 in Review

Legacy Financial Group (Iowa) sold out of TherapeuticsMD (TXMD) in Q4 2023, closing a stake of 100 shares — an estimated $302 sold.

Legacy Financial Group (Iowa) first reported a position in TXMD in Q3 2023 and held it in 1 quarter. The position peaked at $302 in Q3 2023. 39 funds tracked by Wall St. Rank hold TXMD as of Q4 2023.

  • Legacy Financial Group (Iowa) reported no remaining TherapeuticsMD position as of Q4 2023 after selling out during the quarter.
  • Legacy Financial Group (Iowa) sold 100 TherapeuticsMD shares in Q4 2023, an estimated $302.
  • Legacy Financial Group (Iowa) first reported a position in TherapeuticsMD in Q3 2023 and held it in 1 quarter.
  • Legacy Financial Group (Iowa)'s TherapeuticsMD position peaked at $302 in Q3 2023.
  • 39 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2023.

Based on Legacy Financial Group (Iowa)'s 13F filing for Q4 2023, filed 22 Jan 2024.